Skip to main content
. 2019 Sep 25;5(9):FSO421. doi: 10.2144/fsoa-2019-0081

Figure 4. . Progression-free survival analysis in participants treated with first-line chemoimmunotherapy versus standard chemotherapy regimen.

Figure 4. 

Figure 4. 

(A) Pooled HR for PFS in patients with advanced NSCLC treated with first-line chemoimmunotherapy. (B) Pooled HR for PFS in patients with advanced squamous NSCLC treated with first-line chemoimmunotherapy. (C) Pooled HR for PFS in patients with advanced nonsquamous NSCLC treated with first-line chemoimmunotherapy. (D) Pooled HR for PFS in patients with advanced NSCLC treated with PD-1 inhibitor (nivolumab or pembrolizumab) in combination with chemotherapy in the first-line setting. (E) Pooled HR for PFS in patients with advanced NSCLC treated with PD-L1 inhibitor (atezolizumab) in combination with chemotherapy in the first-line setting. (F) Pooled HR for PFS in PD-L1 negative patients with advanced NSCLC in the first-line setting. (G) Pooled HR for PFS in PD-L1 low patients with advanced NSCLC in the first-line setting. (H) Pooled HR for PFS in PD-L1 high patients with advanced NSCLC in the first-line setting. (I) Pooled HR for PFS in patients with EGFR and ALK mutated advanced NSCLC treated with atezolizumab.

HR: Hazard ratio; NSCLC: Non-small-cell lung cancer; OS: Overall survival; PD-1: Programmed death receptor 1; PD-L1: Programmed death ligand 1; PFS: Progression-free survival.